Daiichi Sankyo has formed a new consortium focused on research and discovery of medicines over a period of five years to treat intractable immune-mediated inflammatory diseases.

The Immune-mediated Inflammatory Diseases Consortium for Drug Development has been launched in alliance with other Japanese pharmaceutical organisations and companies, such as Keio University , Ono Pharmaceutical , the National Institutes of Biomedical Innovation, Health and Nutrition and Mitsubishi Tanabe Pharma .

While scientists are conducting reverse translational research globally to find new drugs for intractable immune-mediated inflammatory conditions, the volume of clinical samples from these patients is limited and costs are high.

Daiichi Sankyo noted that the new partnership with various academia and industry members is intended to address these challenges to efficient drug discovery.

“The new partnership with various academia and industry members is intended to address challenges to efficient drug discovery.”

Keio University Hospital and Kochi University will be responsible for the collection of clinical samples and detailed information before as well as after the treatment of patients.

The National Institutes of Biomedical Innovation, Health and Nutrition will carry out detailed and comprehensive analysis, including transcriptome analysis, on the obtained samples.

A database of different data types will be assembled by the consortium and shared with the participating academic institutions and pharmaceutical companies.

Each company will then use the database to perform original drug discovery research for these conditions, while the academia members will leverage findings from the study to advance basic and applied research.

Daiichi Sankyo considers the intractable and rare diseases as difficult-to-cure cases with the use of existing standards and wants to provide new treatment options through the continuous creation of advanced pharmaceuticals.